Is MRNA or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Scholar Rock N/A -163.52% -96.67%

Does the media prefer MRNA or SRRK?

In the previous week, Moderna had 38 more articles in the media than Scholar Rock. MarketBeat recorded 43 mentions for Moderna and 5 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.57 beat Moderna's score of 0.40 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 17 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 10 Negative mention(s) 0 Very Negative mention(s) Neutral Scholar Rock 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is VTRS or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Scholar Rock N/A -163.52% -96.67%

Does the media refer more to VTRS or SRRK?

In the previous week, Scholar Rock had 2 more articles in the media than Viatris. MarketBeat recorded 5 mentions for Scholar Rock and 3 mentions for Viatris. Scholar Rock's average media sentiment score of 1.57 beat Viatris' score of 0.48 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scholar Rock 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is SRRK or GMAB more profitable?

Genmab A/S has a net margin of 21.05% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Genmab A/S 21.05% 15.34% 8.94%

Does the media favor SRRK or GMAB?

In the previous week, Scholar Rock had 2 more articles in the media than Genmab A/S. MarketBeat recorded 5 mentions for Scholar Rock and 3 mentions for Genmab A/S. Scholar Rock's average media sentiment score of 1.57 beat Genmab A/S's score of 0.00 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ASND or SRRK?

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Scholar Rock. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 5 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.57 beat Ascendis Pharma A/S's score of 1.16 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to AXSM or SRRK?

In the previous week, Axsome Therapeutics had 4 more articles in the media than Scholar Rock. MarketBeat recorded 9 mentions for Axsome Therapeutics and 5 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.57 beat Axsome Therapeutics' score of 1.01 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Scholar Rock (SRRK) Competitors

$51.27 +2.08 (+4.23%)

Closing price 04:00 PM Eastern

Extended Trading

$50.62 -0.66 (-1.28%)

As of 06:30 PM Eastern

Compare

SRRK vs. MRNA, VTRS, GMAB, ASND, and AXSM

Should you buy Scholar Rock stock or one of its competitors? MarketBeat compares Scholar Rock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scholar Rock include Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Scholar Rock compare to Moderna?

Moderna (NASDAQ:MRNA) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

In the previous week, Moderna had 38 more articles in the media than Scholar Rock. MarketBeat recorded 43 mentions for Moderna and 5 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.57 beat Moderna's score of 0.40 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	17 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	10 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scholar Rock	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Moderna presently has a consensus price target of $36.60, indicating a potential downside of 40.00%. Scholar Rock has a consensus price target of $56.00, indicating a potential upside of 9.23%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts clearly believe Scholar Rock is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

75.3% of Moderna shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Scholar Rock has lower revenue, but higher earnings than Moderna. Scholar Rock is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	12.45	-$2.82B	-$8.15	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Scholar Rock has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Scholar Rock	N/A	-163.52%	-96.67%

Summary

Scholar Rock beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Viatris?

Viatris (NASDAQ:VTRS) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Scholar Rock has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.28	-$3.51B	-$0.26	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Viatris currently has a consensus target price of $17.50, suggesting a potential upside of 11.11%. Scholar Rock has a consensus target price of $56.00, suggesting a potential upside of 9.23%. Given Viatris' higher probable upside, analysts clearly believe Viatris is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Scholar Rock has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Scholar Rock	N/A	-163.52%	-96.67%

In the previous week, Scholar Rock had 2 more articles in the media than Viatris. MarketBeat recorded 5 mentions for Scholar Rock and 3 mentions for Viatris. Scholar Rock's average media sentiment score of 1.57 beat Viatris' score of 0.48 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scholar Rock	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

79.9% of Viatris shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 13.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Summary

Scholar Rock beats Viatris on 10 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Genmab A/S?

Scholar Rock (NASDAQ:SRRK) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

In the previous week, Scholar Rock had 2 more articles in the media than Genmab A/S. MarketBeat recorded 5 mentions for Scholar Rock and 3 mentions for Genmab A/S. Scholar Rock's average media sentiment score of 1.57 beat Genmab A/S's score of 0.00 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scholar Rock currently has a consensus target price of $56.00, indicating a potential upside of 9.23%. Genmab A/S has a consensus target price of $37.93, indicating a potential upside of 46.22%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Genmab A/S	$3.72B	4.35	$963M	$1.32	19.65

Genmab A/S has a net margin of 21.05% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Genmab A/S	21.05%	15.34%	8.94%

Scholar Rock has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Summary

Genmab A/S beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Ascendis Pharma A/S has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.27	-$258M	$8.67	27.52
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Ascendis Pharma A/S has a net margin of 57.87% compared to Scholar Rock's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Scholar Rock	N/A	-163.52%	-96.67%

Ascendis Pharma A/S has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Scholar Rock. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 5 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.57 beat Ascendis Pharma A/S's score of 1.16 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Ascendis Pharma A/S presently has a consensus price target of $295.39, indicating a potential upside of 23.81%. Scholar Rock has a consensus price target of $56.00, indicating a potential upside of 9.23%. Given Ascendis Pharma A/S's higher probable upside, equities research analysts plainly believe Ascendis Pharma A/S is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

91.1% of Scholar Rock shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Ascendis Pharma A/S beats Scholar Rock on 11 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Axsome Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 13.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Scholar Rock has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Scholar Rock's return on equity of -163.52% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Scholar Rock	N/A	-163.52%	-96.67%

Axsome Therapeutics presently has a consensus target price of $258.95, suggesting a potential upside of 7.02%. Scholar Rock has a consensus target price of $56.00, suggesting a potential upside of 9.23%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts clearly believe Scholar Rock is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

In the previous week, Axsome Therapeutics had 4 more articles in the media than Scholar Rock. MarketBeat recorded 9 mentions for Axsome Therapeutics and 5 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.57 beat Axsome Therapeutics' score of 1.01 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Axsome Therapeutics has higher revenue and earnings than Scholar Rock. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.50	-$183.17M	-$3.73	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Summary

Scholar Rock beats Axsome Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Scholar Rock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRRK vs. The Competition

Export

Metric	Scholar Rock	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.89B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-14.28	19.75	24.92	23.97
Price / Sales	N/A	329.42	528.81	109.59
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	21.27	8.29	10.79	6.50
Net Income	-$377.94M	$23.85M	$3.56B	$336.88M
7 Day Performance	12.53%	5.21%	1.67%	-0.22%
1 Month Performance	6.52%	2.19%	0.43%	0.77%
1 Year Performance	54.06%	60.99%	32.84%	31.57%

Scholar Rock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRRK Scholar Rock	2.1126 of 5 stars	$51.27 +4.2%	$56.00 +9.2%	+44.5%	$5.89B	N/A	N/A	140	Positive News
MRNA Moderna	1.2411 of 5 stars	$52.13 +4.4%	$36.60 -29.8%	+129.2%	$19.80B	$1.94B	N/A	4,700
VTRS Viatris	3.2693 of 5 stars	$16.32 -1.0%	$17.50 +7.2%	+73.4%	$19.19B	$14.30B	N/A	30,000	News Coverage
GMAB Genmab A/S	4.0239 of 5 stars	$24.58 -2.0%	$37.93 +54.3%	+21.0%	$15.64B	$3.72B	18.62	3,029	Analyst Forecast Options Volume
ASND Ascendis Pharma A/S	4.9172 of 5 stars	$223.29 +2.4%	$295.39 +32.3%	+28.9%	$13.60B	$814.57M	25.75	1,189	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRRK) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scholar Rock (SRRK) Competitors

SRRK vs. MRNA, VTRS, GMAB, ASND, and AXSM

How does Scholar Rock compare to Moderna?

Summary

How does Scholar Rock compare to Viatris?

Summary

How does Scholar Rock compare to Genmab A/S?

Summary

How does Scholar Rock compare to Ascendis Pharma A/S?

Summary

How does Scholar Rock compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scholar Rock (SRRK) Competitors

SRRK vs. MRNA, VTRS, GMAB, ASND, and AXSM

How does Scholar Rock compare to Moderna?

Does the media prefer MRNA or SRRK?

Do analysts recommend MRNA or SRRK?

Do insiders & institutionals believe in MRNA or SRRK?

Which has better earnings and valuation, MRNA or SRRK?

Which has more volatility and risk, MRNA or SRRK?

Is MRNA or SRRK more profitable?

Summary

How does Scholar Rock compare to Viatris?

Which has preferable earnings & valuation, VTRS or SRRK?

Do analysts rate VTRS or SRRK?

Is VTRS or SRRK more profitable?

Does the media refer more to VTRS or SRRK?

Do insiders & institutionals have more ownership in VTRS or SRRK?

Which has more volatility & risk, VTRS or SRRK?

Summary

How does Scholar Rock compare to Genmab A/S?

Does the media favor SRRK or GMAB?

Do analysts rate SRRK or GMAB?

Do insiders and institutionals have more ownership in SRRK or GMAB?

Which has higher valuation & earnings, SRRK or GMAB?

Is SRRK or GMAB more profitable?

Which has more risk and volatility, SRRK or GMAB?

Summary

How does Scholar Rock compare to Ascendis Pharma A/S?

Which has higher valuation & earnings, ASND or SRRK?

Is ASND or SRRK more profitable?

Which has more risk & volatility, ASND or SRRK?

Does the media prefer ASND or SRRK?

Do analysts rate ASND or SRRK?

Do insiders & institutionals believe in ASND or SRRK?

Summary

How does Scholar Rock compare to Axsome Therapeutics?

Which has more risk and volatility, AXSM or SRRK?

Do insiders and institutionals hold more shares of AXSM or SRRK?

Is AXSM or SRRK more profitable?

Do analysts rate AXSM or SRRK?

Does the media refer more to AXSM or SRRK?

Which has better earnings and valuation, AXSM or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools